SAN DIEGO --(BUSINESS WIRE)--May 18, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”) will be held in a virtual-only format due to continued public health

SAN DIEGO --(BUSINESS WIRE)--May 13, 2020-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem” or, the “Company”) announced today the pricing of $250.0 million aggregate principal amount of 1.50 percent Convertible Senior Notes due 2025 (the “Notes”) in a private placement to persons reasonably

SAN DIEGO --(BUSINESS WIRE)--May 12, 2020-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem” or, the “Company”) announced today that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”)

SAN DIEGO --(BUSINESS WIRE)--May 7, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan , president and chief executive officer, will present a company update at the following virtual investor conferences:

Second Quarter 2020 Sales Guidance Provided, Annual Guidance Withdrawn SAN DIEGO --(BUSINESS WIRE)--Apr. 30, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2020 .

SAN DIEGO --(BUSINESS WIRE)--Apr. 9, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2020 results after the financial markets close on Thursday, April 30, 2020 .

SAN DIEGO --(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) today announced that it will be notifying its customers of an information security incident involving five Tandem employee email accounts. On January 17, 2020 , the Company learned that an unauthorized user gained access to an

SAN DIEGO --(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of its Basal-IQ™ technology as an interoperable automated glycemic controller (iAGC).

SAN DIEGO --(BUSINESS WIRE)--Feb. 24, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2019 and financial guidance for the year ending December 31, 2020 .

MADRID --(BUSINESS WIRE)--Feb. 20, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced positive data presented today on its automated insulin delivery technologies, including data from a study of the t:slim X2™ insulin pump with

SAN DIEGO --(BUSINESS WIRE)--Feb. 14, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming investor conferences: SVB Leerink 9 th Annual Global Healthcare Conference on

SAN DIEGO --(BUSINESS WIRE)--Jan. 27, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2019 results after the financial markets close on Monday, February 24, 2020 .

SAN DIEGO --(BUSINESS WIRE)--Jan. 15, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its commercial launch of the t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid-closed loop feature designed to

SAN DIEGO --(BUSINESS WIRE)--Jan. 9, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Elizabeth Gasser as its new Executive Vice President, Strategy and Corporate Development.

Automated Insulin Dosing Software First to Receive New Classification by FDA SAN DIEGO --(BUSINESS WIRE)--Dec. 13, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration ( FDA ) clearance of the

SAN DIEGO --(BUSINESS WIRE)--Nov. 20, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada approval of the t:slim X2™ insulin pump with Basal-IQ™ technology. Basal-IQ technology, a predictive low-glucose suspend

SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming investor conferences: Credit Suisse 28 th Annual Healthcare Conference on

SAN DIEGO --(BUSINESS WIRE)--Nov. 4, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2019 and updated its financial guidance for the year ending December 31, 2019 .

SAN DIEGO --(BUSINESS WIRE)--Nov. 1, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, is supporting the efforts of Beyond Type 1, a global diabetes advocacy organization, in fielding its largest marathon team in history, made up of 30

SAN DIEGO --(BUSINESS WIRE)--Oct. 30, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend